Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHX1901 in non-segmental vitiligo
NCT06511739Phase 2Recruiting
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- May 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SYHX-1901 in Vitiligo (4 arms), sponsored by CSPC Ouyi Pharmaceutical. Primary endpoint: Percent Change From Baseline in Facial-Vitiligo Area Scoring Index at 24 weeks. Started May 2024; status: recruiting.
02
Drugs
SYHX-1901
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT06511739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06511739.